Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease
Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.
Archives for November 19, 2024
C Ray Therapeutics raises $100 million to develop radiopharmaceuticals
The financing round will fund the improvement of the company’s technology platform for the discovery and development of innovative radionuclide drug conjugates.